Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wildon Farwell

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
The New England Journal of Medicine|February 1, 2018
Therapy for Spinal Muscular AtrophyRichard S Finkel, Wildon Farwell
Advances in Therapy|September 13, 2019
Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8Alfred W Sandrock, Wildon Farwell
Journal of the American Geriatrics Society|October 2, 2009
Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare systemRohini K Hernandez, Wildon Farwell, Michael D Cantor, et al.
Journal of Neuromuscular Diseases|February 22, 2021
14-Year Changes in Plasma Neurofilament Levels Among Men: A Pilot StudyPamela M Rist, Varant Kupelian, Marco Petrillo, et al.
Orphanet Journal of Rare Diseases|November 30, 2017
Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United StatesCathy Lally, Cynthia Jones, Wildon Farwell, et al.
Blood Cells, Molecules & Diseases|February 9, 2017
The targeted eosinophil-lowering effects of dexpramipexole in clinical studiesSteven I Dworetzky, Gregory T Hebrank, Donald G Archibald, et al.
Journal of Clinical Pharmacology|June 27, 2014
Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal functionPing He, Doug Kerr, Thomas Marbury, et al.
Journal of Neuromuscular Diseases|November 11, 2019
Spinal Muscular Atrophy (SMA) Subtype Concordance in Siblings: Findings From the Cure SMA CohortCynthia C Jones, Suzanne F Cook, Jill Jarecki, et al.
CNS Drugs|August 18, 2019
An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical TrialsBasil T Darras, Michelle A Farrar, Eugenio Mercuri, et al.
Journal of Neuromuscular Diseases|June 6, 2018
Position Statement: Sharing of Clinical Research Data in Spinal Muscular Atrophy to Accelerate Research and Improve Outcomes for PatientsHanns Lochmüller, David Evans, Wildon Farwell, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
The New England Journal of Medicine|February 1, 2018
Therapy for Spinal Muscular AtrophyRichard S Finkel, Wildon Farwell
Advances in Therapy|September 13, 2019
Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8Alfred W Sandrock, Wildon Farwell
Journal of the American Geriatrics Society|October 2, 2009
Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare systemRohini K Hernandez, Wildon Farwell, Michael D Cantor, et al.
Journal of Neuromuscular Diseases|February 22, 2021
14-Year Changes in Plasma Neurofilament Levels Among Men: A Pilot StudyPamela M Rist, Varant Kupelian, Marco Petrillo, et al.
Orphanet Journal of Rare Diseases|November 30, 2017
Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United StatesCathy Lally, Cynthia Jones, Wildon Farwell, et al.
Blood Cells, Molecules & Diseases|February 9, 2017
The targeted eosinophil-lowering effects of dexpramipexole in clinical studiesSteven I Dworetzky, Gregory T Hebrank, Donald G Archibald, et al.
Journal of Clinical Pharmacology|June 27, 2014
Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal functionPing He, Doug Kerr, Thomas Marbury, et al.
Journal of Neuromuscular Diseases|November 11, 2019
Spinal Muscular Atrophy (SMA) Subtype Concordance in Siblings: Findings From the Cure SMA CohortCynthia C Jones, Suzanne F Cook, Jill Jarecki, et al.
CNS Drugs|August 18, 2019
An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical TrialsBasil T Darras, Michelle A Farrar, Eugenio Mercuri, et al.
Journal of Neuromuscular Diseases|June 6, 2018
Position Statement: Sharing of Clinical Research Data in Spinal Muscular Atrophy to Accelerate Research and Improve Outcomes for PatientsHanns Lochmüller, David Evans, Wildon Farwell, et al.
Pageof 3